Alligamycin A, an unprecedented antifungal β-lactone spiroketal macrolide from Streptomyces iranensis
Zhijie Yang,Yijun Qiao,Emil Strøbech,Jens Preben Morth,Grit Walther,Tue Sparholt Jørgensen,Gundela Peschel,Miriam Agler Rosenbaum,Viola Previtali,Mads Hartvig Clausen,Marie Vestergaard Lukassen,Charlotte Held Gotfredsen,Oliver Kurzai,Tilmann Weber,Ling Ding
DOI: https://doi.org/10.1101/2024.04.17.589928
2024-08-27
Abstract:Fungal infections pose a great threat to public health and there are limited antifungal medicaments. Streptomyces is an important source of antibiotics, represented by the clinical drug amphotericin B. The rapamycin-producer Streptomyces iranensis harbors an unparalleled Type I polyketide synthase, which codes for a novel antifungal macrolide alligamycin A (1), the structure of which was confirmed by NMR, MS, and X-ray crystallography. Alligamycin A harbors an undescribed carbon skeleton with 13 chiral centers, featuring a β-lactone moiety, a [6,6]-spiroketal ring, and an unprecedented 7-oxo-octylmalonyl-CoA extender unit incorporated by a potential novel crotonyl-CoA carboxylase/reductase. The ali biosynthetic gene cluster was confirmed through CRISPR-based gene editing. Alligamycin A displayed profound antifungal effects against numerous clinically relevant filamentous fungi, including Talaromyces and Aspergillus species. β-Lactone ring is essential for the antifungal activity and alligamycin B (2) with disruption in the ring abolished the antifungal effect. Proteomics analysis revealed alligamycin A potentially disrupted the integrity of fungal cell walls and induced the expression of stress-response proteins in Aspergillus niger. Alligamycins represent a new class of potential drug candidate to combat fungal infections.
Biochemistry